The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death

被引:0
|
作者
Mohamed El-Mesery
Tina Rosenthal
Hilka Rauert-Wunderlich
Martin Schreder
Thorsten Stühmer
Ellen Leich
Andreas Schlosser
Martin Ehrenschwender
Harald Wajant
Daniela Siegmund
机构
[1] Mansoura University,Department of Biochemistry, Faculty of Pharmacy
[2] University Hospital Würzburg,Division of Molecular Internal Medicine, Department of Internal Medicine II
[3] University of Würzburg,Institute of Pathology
[4] University Hospital Würzburg,Comprehensive Cancer Center Mainfranken
[5] University Hospital Würzburg,Lehrstuhl für Translationale Onkologie, Comprehensive Cancer Center Mainfranken
[6] University of Würzburg,Rudolf Virchow Center for Experimental Biomedicine
[7] University Hospital Regensburg,Institute of Clinical Microbiology and Hygiene
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The NEDD8-activating enzyme (NAE) inhibitor MLN4924 inhibits cullin-RING ubiquitin ligase complexes including the SKP1-cullin-F-box E3 ligase βTrCP. MLN4924 therefore inhibits also the βTrCP-dependent activation of the classical and the alternative NFĸB pathway. In this work, we found that a subgroup of multiple myeloma cell lines (e.g., RPMI-8226, MM.1S, KMS-12BM) and about half of the primary myeloma samples tested are sensitized to TNF-induced cell death by MLN4924. This correlated with MLN4924-mediated inhibition of TNF-induced activation of the classical NFκB pathway and reduced the efficacy of TNF-induced TNFR1 signaling complex formation. Interestingly, binding studies revealed a straightforward correlation between cell surface TNFR1 expression in multiple myeloma cell lines and their sensitivity for MLN4924/TNF-induced cell death. The cell surface expression levels of TNFR1 in the investigated MM cell lines largely correlated with TNFR1 mRNA expression. This suggests that the variable levels of cell surface expression of TNFR1 in myeloma cell lines are decisive for TNF/MLN4924 sensitivity. Indeed, introduction of TNFR1 into TNFR1-negative TNF/MLN4924-resistant KMS-11BM cells, was sufficient to sensitize this cell line for TNF/MLN4924-induced cell death. Thus, MLN4924 might be especially effective in myeloma patients with TNFR1+ myeloma cells and a TNFhigh tumor microenvironment.
引用
收藏
相关论文
共 50 条
  • [21] Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program
    Smith, Malcolm A.
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Morton, Christopher L.
    Wu, Jianrong
    Smith, Peter G.
    Yu, Jie
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2012, 59 (02) : 246 - 253
  • [22] Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen
    Yan, Zhong-Hua
    Burkhardt, Anne
    Loke, Huay-Keng
    Chen, Jesse
    Xu, Qing
    Brauer, Pam
    Ma, Jingya
    Lin, Yafang
    Garcia, Khris
    Dick, Lawrence R.
    Bembenek, Michael E.
    ANALYTICAL BIOCHEMISTRY, 2013, 439 (02) : 109 - 115
  • [23] AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor
    Chen, Xiaoyu
    Cui, Danrui
    Bi, Yanli
    Shu, Jianfeng
    Xiong, Xiufang
    Zhao, Yongchao
    CELL CYCLE, 2018, 17 (16) : 2069 - 2079
  • [24] Pediatric Preclinical Testing Program (PPTP) evaluation of the NEDD8-activating enzyme (NAE) inhibitor MLN4924
    Carol, Hernan
    Lock, Richard B.
    Maris, John M.
    Keir, Stephen T.
    Gorlick, Richard
    Kolb, E. Anders
    Kang, Min H.
    Reynolds, C. Patrick
    Morton, Christopher L.
    Smith, Peter G.
    Thomas, Michael
    McDonald, Alice
    Houghton, Peter J.
    Smith, Malcolm A.
    CANCER RESEARCH, 2011, 71
  • [25] Stereoselective Synthesis of MLN4924, an Inhibitor of NEDD8-Activating Enzyme (vol 76, pg 3557, 2011)
    Lee, Hyuk Woo
    Nam, Soo Kyung
    Choi, Won Jun
    Kim, Hea Ok
    Jeong, Lak Shin
    JOURNAL OF ORGANIC CHEMISTRY, 2011, 76 (09): : 3614 - 3614
  • [26] MLN4924, a First-in-Class NEDD8-Activating Enzyme Inhibitor, Attenuates IFN-β Production
    Song, Hui
    Huai, Wanwan
    Yu, Zhongxia
    Wang, Wenwen
    Zhao, Jing
    Zhang, Lining
    Zhao, Wei
    JOURNAL OF IMMUNOLOGY, 2016, 196 (07): : 3117 - 3123
  • [27] Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
    Milhollen, Michael A.
    Thomas, Michael P.
    Narayanan, Usha
    Traore, Tary
    Riceberg, Jessica
    Amidon, Benjamin S.
    Bence, Neil F.
    Bolen, Joseph B.
    Brownell, James
    Dick, Lawrence R.
    Loke, Huay-Keng
    McDonald, Alice A.
    Ma, Jingya
    Manfredi, Mark G.
    Sells, Todd B.
    Sintchak, Mike D.
    Yang, Xiaofeng
    Xu, Qing
    Koenig, Erik M.
    Gavin, James M.
    Smith, Peter G.
    CANCER CELL, 2012, 21 (03) : 388 - 401
  • [28] Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma
    Shah, Jatin J.
    Jakubowiak, Andrzej J.
    O'Connor, Owen A.
    Orlowski, Robert Z.
    Harvey, R. Donald
    Smith, Mitchell R.
    Lebovic, Daniel
    Diefenbach, Catherine
    Kelly, Kevin
    Hua, Zhaowei
    Berger, Allison J.
    Mulligan, George
    Faessel, Helene M.
    Tirrell, Stephen
    Dezube, Bruce J.
    Lonial, Sagar
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 34 - 43
  • [29] Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
    Xu, G. Wei
    Toth, Julia I.
    da Silva, Sara R.
    Paiva, Stacey-Lynn
    Lukkarila, Julie L.
    Hurren, Rose
    Maclean, Neil
    Sukhai, Mahadeo A.
    Bhattacharjee, Rabindra N.
    Goard, Carolyn A.
    Gunning, Patrick T.
    Dhe-Paganon, Sirano
    Petroski, Matthew D.
    Schimmer, Aaron D.
    PLOS ONE, 2014, 9 (04):
  • [30] Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
    Wang, Xiaofang
    Zhang, Wenjuan
    Yan, Zi
    Liang, Yupei
    Li, Lihui
    Yu, Xiaoli
    Feng, Yan
    Fu, Shen
    Zhang, Yanmei
    Zhao, Hu
    Yu, Jinha
    Jeong, Lak Shin
    Guo, Xiaomao
    Jia, Lijun
    ONCOTARGET, 2016, 7 (25) : 38380 - 38391